In re Darvocet, Darvon & Propoxyphene Products Liability Litigation

939 F. Supp. 2d 1376, 2013 WL 1635469, 2013 U.S. Dist. LEXIS 54107
CourtUnited States Judicial Panel on Multidistrict Litigation
DecidedApril 17, 2013
DocketMDL No. 2226
StatusPublished
Cited by2 cases

This text of 939 F. Supp. 2d 1376 (In re Darvocet, Darvon & Propoxyphene Products Liability Litigation) is published on Counsel Stack Legal Research, covering United States Judicial Panel on Multidistrict Litigation primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Darvocet, Darvon & Propoxyphene Products Liability Litigation, 939 F. Supp. 2d 1376, 2013 WL 1635469, 2013 U.S. Dist. LEXIS 54107 (jpml 2013).

Opinion

TRANSFER ORDER

JOHN G. HEYBURN II, Chairman.

Before the Panel: Pursuant to Panel Rule 7. 1, plaintiffs in three actions listed on Schedule A move to vacate our order that conditionally transferred their actions to MDL No. 2226. Responding defendant Eli Lilly & Co. (Eli Lilly) supports the motions to the extent that they are based on the argument that each action was removed as a “mass action” under the Class Action Fairness Act of 2005 (CAFA) and, therefore, cannot be transferred by the Panel without the request of a majority of the plaintiffs in each. See 28 U.S.C. § 1332(d)(ll)(C)(i). Eli Lilly disagrees, however, with plaintiffs’ remaining argur ments.

I. Plaintiffs’ Non-CAFA Arguments Against Transfer

Before we turn to the CAFA issue, we address plaintiffs’ other arguments against transfer. After careful review of the record, we find it clear that these three actions share questions of fact with actions in this litigation previously transferred to the Eastern District of Kentucky, and that transfer of these actions to MDL No. 2226 will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. Like many of the already-centralized actions, the actions before the Panel involve factual questions arising from allegations that Darvocet, Darvon .and other medications containing propoxyphene were defectively designed and marketed and that ingestion of such medications resulted in injury. See In re: Darvocet, Darvon and Propoxyphene Prods. Liab. Litig., 780 F.Supp.2d 1379, 1380 (J.P.M.L.2011).

Plaintiffs argue that federal jurisdiction is lacking, and that their cases involve unique issues of fact. We have often held, however, that jurisdictional issues, such as a claimed lack of diversity or absence of a federal question, do not present an impediment to transfer, as plaintiffs can present such arguments to the transferee judge. See, e.g., In re: Prudential Ins. Co. of Am. Sales Practices Litig., 170 F.Supp.2d 1346, 1347-48 (J.P.M.L.2001). Moreover, while these actions may involve some unique issues of fact, the majority of claims are virtually identical to claims already pending in the MDL. Section 1407 does not require a complete identity or even a majority of common factual or legal issues as a prerequisite to transfer. See, e.g., Gadolinium Contrast Dyes Prods. Liab. Litig., 536 F.Supp.2d 1380, 1382 (J.P.M.L.2008).

It is not only the jurisdiction of the federal courts that plaintiffs challenge, however, but also this Panel’s authority to transfer these actions pursuant to 28 U.S.C. § 1407. Therefore, we must determine whether CAFA’s mass action provision presents. an obstacle to transfer of these cases. We turn to that issue now.

II. CAFA’s Mass Action Provision

Enacted in 2005, CAFA changed the rules for diversity jurisdiction and re[1378]*1378moval, allowing most large class actions to be filed in, or removed to, federal court. Concerned that abuses in state court class action litigation (e.g., essentially worthless coupon settlements, unjustified awards, and excessive counsel fees) were “under-minting] the national judicial system,” Congress determined to expand access to the federal courts for class action litigation, explaining: “Class action lawsuits are an important and valuable part of the legal system when they permit the fair and efficient resolution of legitimate claims of numerous parties by allowing the claims to be aggregated into a single action against a defendant that has allegedly caused harm.” See Pub.L. No. 109-2, 119 Stat. 4, Sec. 2(a)(l)-(4). Congress’s emphasis on the “fair and efficient resolution” of common claims suggests that CAFA was intended also to expand access to federal multidistrict litigation for such> newly-removable actions. Indeed, the statute’s legislative history squarely supports that suggestion. See, e.g., S. Rep. No. 109-14.at 38 (2005), 2005 U.S.C.C.A.N. 3, 37 (Conf. Rep.) (“If other class actions on the same subject have been (or are likely to be) filed elsewhere, the Committee intends that this consideration would strongly favor the exercise of federal jurisdiction so that the claims of all proposed classes could be handled efficiently on a Coordinated basis pursuant to the federal courts’ multidistrict litigation process as established by 28 U.S.C. § 1407.”).

In addition to expanding ac’cess to federal courts for class actions, CAFA expanded access to the federal courts for a new category of cases called “mass actions.” The statute’s mass action provision authorizes removal of an action where: (1) the monetary relief claims of 100 or more persons are proposed to be tried jointly on the ground that their claims involve common questions of law or fact; (2) the aggregate amount in controversy exceeds $5 million; (3) the claims of the individual plaintiffs each exceed. $75,000; and (4) minimal diversity exists. See 28 U.S.C. § 1332(d)(ll). At the same time, however, CAFA limited the Panel’s authority to transfer actions removed as “mass actions.” See § 1332(d)(ll)(C)(i) (“Any actions) removed to Federal court pursuant to this subsection shall not thereafter be transferred to any other court pursuant to section 1407, or the rules promulgated thereunder, unless a majority of the plaintiffs in the action request transfer pursuant to section 1407.”).

It is Section 1332(d)(ll)(C)(i) upon which the parties before us base their objections to transfer. In each notice of removal filed in the three actions, removing defendants proffered two .or three grounds for removal. The notices of removal all cite federal question jurisdiction and CAFA’s mass action provision as bases for removal, and the notices in two actions cite also diversity jurisdiction. While the language of Section 1332(d)(ll)(C)(i) clearly .circumscribes the Panel’s authority to transfer an action removed solely as a mass action, we are confronted with the question whether the provision applies to an action that has been removed on multiple bases, including as a mass action.

In the past, when the issue of transfer of actions removed on mass action and other grounds has come before us, we have postponed a decision on transfer pending a ruling on plaintiffs’ motions to remand to state court in the involved actions, in order to permit the putative transferor courts to rule on those motions, and thus determine the ground or grounds (if any) on which removal was proper.1 Given the possibility [1379]*1379that those actions would be remanded to state court, which would moot the issue of Section 1407 transfer, we thought it best, at that time, not to reach the issue of the precise impact of Section 1332(d)(ll)(C)(i). This scenario has arisen with increasing frequency, however, and having now had the opportunity to consider the issue fully, we find that a decision at this time is appropriate.

III. Interpretation of 28 U.S.C. § 1332(d)(ll)(C)(i)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bowen v. McKesson Corp.
106 F. Supp. 3d 849 (E.D. Kentucky, 2015)
In re State Farm Lloyds Hidalgo County Hail Storm Litigation
434 S.W.3d 350 (Texas Judicial Panel on Multidistrict Litigation, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
939 F. Supp. 2d 1376, 2013 WL 1635469, 2013 U.S. Dist. LEXIS 54107, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-darvocet-darvon-propoxyphene-products-liability-litigation-jpml-2013.